S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   399.76 (+2.19%)
AAPL   160.60 (+2.42%)
MSFT   337.70 (+2.43%)
FB   338.30 (+1.55%)
GOOGL   2,910.18 (+2.34%)
AMZN   3,587.68 (+2.37%)
TSLA   1,141.09 (+5.47%)
NVDA   328.62 (+4.31%)
BABA   131.90 (-1.09%)
NIO   40.14 (+0.38%)
CGC   11.15 (-4.62%)
AMD   159.52 (+3.04%)
GE   98.52 (+0.70%)
MU   84.98 (+1.87%)
T   24.00 (-0.91%)
F   19.81 (+0.30%)
DIS   147.12 (-0.67%)
ACB   6.49 (-4.42%)
AMC   36.88 (-1.99%)
PFE   53.76 (-0.44%)
BA   198.24 (-0.49%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   399.76 (+2.19%)
AAPL   160.60 (+2.42%)
MSFT   337.70 (+2.43%)
FB   338.30 (+1.55%)
GOOGL   2,910.18 (+2.34%)
AMZN   3,587.68 (+2.37%)
TSLA   1,141.09 (+5.47%)
NVDA   328.62 (+4.31%)
BABA   131.90 (-1.09%)
NIO   40.14 (+0.38%)
CGC   11.15 (-4.62%)
AMD   159.52 (+3.04%)
GE   98.52 (+0.70%)
MU   84.98 (+1.87%)
T   24.00 (-0.91%)
F   19.81 (+0.30%)
DIS   147.12 (-0.67%)
ACB   6.49 (-4.42%)
AMC   36.88 (-1.99%)
PFE   53.76 (-0.44%)
BA   198.24 (-0.49%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   399.76 (+2.19%)
AAPL   160.60 (+2.42%)
MSFT   337.70 (+2.43%)
FB   338.30 (+1.55%)
GOOGL   2,910.18 (+2.34%)
AMZN   3,587.68 (+2.37%)
TSLA   1,141.09 (+5.47%)
NVDA   328.62 (+4.31%)
BABA   131.90 (-1.09%)
NIO   40.14 (+0.38%)
CGC   11.15 (-4.62%)
AMD   159.52 (+3.04%)
GE   98.52 (+0.70%)
MU   84.98 (+1.87%)
T   24.00 (-0.91%)
F   19.81 (+0.30%)
DIS   147.12 (-0.67%)
ACB   6.49 (-4.42%)
AMC   36.88 (-1.99%)
PFE   53.76 (-0.44%)
BA   198.24 (-0.49%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   399.76 (+2.19%)
AAPL   160.60 (+2.42%)
MSFT   337.70 (+2.43%)
FB   338.30 (+1.55%)
GOOGL   2,910.18 (+2.34%)
AMZN   3,587.68 (+2.37%)
TSLA   1,141.09 (+5.47%)
NVDA   328.62 (+4.31%)
BABA   131.90 (-1.09%)
NIO   40.14 (+0.38%)
CGC   11.15 (-4.62%)
AMD   159.52 (+3.04%)
GE   98.52 (+0.70%)
MU   84.98 (+1.87%)
T   24.00 (-0.91%)
F   19.81 (+0.30%)
DIS   147.12 (-0.67%)
ACB   6.49 (-4.42%)
AMC   36.88 (-1.99%)
PFE   53.76 (-0.44%)
BA   198.24 (-0.49%)
NASDAQ:ASRT

Assertio Stock Forecast, Price & News

$1.48
-0.06 (-3.90%)
(As of 11/29/2021 12:30 PM ET)
Add
Compare
Today's Range
$1.46
$1.56
50-Day Range
$0.86
$1.63
52-Week Range
$0.85
$5.80
Volume
2,323 shs
Average Volume
2.00 million shs
Market Capitalization
$66.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.58
30 days | 90 days | 365 days | Advanced Chart
Receive ASRT News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.


Assertio logo

About Assertio

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASRT
Employees
27
Year Founded
N/A

Sales & Book Value

Annual Sales
$106.28 million
Cash Flow
$0.15 per share
Book Value
$2.17 per share

Profitability

Net Income
$-28.14 million
Pretax Margin
-37.96%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,054,000
Market Cap
$66.06 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

1.10 out of 5 stars

Medical Sector

1219th out of 1,392 stocks

Pharmaceutical Preparations Industry

581st out of 670 stocks

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Assertio (NASDAQ:ASRT) Frequently Asked Questions

Is Assertio a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Assertio stock.
View analyst ratings for Assertio
or view top-rated stocks.

How has Assertio's stock price been impacted by Coronavirus (COVID-19)?

Assertio's stock was trading at $0.9301 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ASRT shares have increased by 59.1% and is now trading at $1.48.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Assertio?

Assertio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,250,000 shares, an increase of 23.8% from the October 31st total of 1,010,000 shares. Based on an average trading volume of 953,700 shares, the short-interest ratio is currently 1.3 days. Approximately 3.0% of the company's stock are short sold.
View Assertio's Short Interest
.

When is Assertio's next earnings date?

Assertio is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Assertio
.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.12. Assertio had a negative trailing twelve-month return on equity of 34.57% and a negative net margin of 28.04%. During the same period last year, the business earned ($0.36) earnings per share.
View Assertio's earnings history
.

Who are Assertio's key executives?

Assertio's management team includes the following people:

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

What is Assertio's stock symbol?

Assertio trades on the NASDAQ under the ticker symbol "ASRT."

Who are Assertio's major shareholders?

Assertio's stock is owned by a variety of retail and institutional investors. Top institutional investors include CI Investments Inc. (1.13%), Geode Capital Management LLC (0.77%), TSP Capital Management Group LLC (0.60%), Perritt Capital Management Inc. (0.49%), Millennium Management LLC (0.16%) and Morgan Stanley (0.16%). Company insiders that own Assertio stock include Ajay Patel, Daniel A Peisert, Group LP Cr, Karen A Dawes and Paul Schwichtenberg.
View institutional ownership trends for Assertio
.

Which major investors are selling Assertio stock?

ASRT stock was sold by a variety of institutional investors in the last quarter, including CI Investments Inc., and HAP Trading LLC.
View insider buying and selling activity for Assertio
or view top insider-selling stocks.

Which major investors are buying Assertio stock?

ASRT stock was acquired by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Perritt Capital Management Inc., Millennium Management LLC, Geode Capital Management LLC, Morgan Stanley, and Citadel Advisors LLC. Company insiders that have bought Assertio stock in the last two years include Ajay Patel, Daniel A Peisert, and Paul Schwichtenberg.
View insider buying and selling activity for Assertio
or or view top insider-buying stocks.

How do I buy shares of Assertio?

Shares of ASRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assertio's stock price today?

One share of ASRT stock can currently be purchased for approximately $1.48.

How much money does Assertio make?

Assertio has a market capitalization of $66.06 million and generates $106.28 million in revenue each year. The company earns $-28.14 million in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Assertio have?

Assertio employs 27 workers across the globe.

What is Assertio's official website?

The official website for Assertio is www.assertiotx.com.

Where are Assertio's headquarters?

How can I contact Assertio?

Assertio's mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The company can be reached via phone at (224) 419-7106, via email at [email protected], or via fax at 510-744-8001.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.